Category Archives: BioEngineering

BOSTON (AP) A Stanford University professor has won a $500,000 award from a Massachusetts Institute of Technology program in recognition of his inventions.

In awarding the 2012 Lemelson-MIT Prize, university officials on Monday called Stephen Quake "a prolific inventor with a fearless ability to explore and work across disciplines."

Quake invented a chip, similar to those in electronic devices, that lets scientists take nearly 10,000 different measurements at once. Through his work, called microfluidic large-scale integration, companies and research organizations are able to use the rubber chip technology in developing cancer drugs.

MIT officials said on the school's website that Quake's research has led to the creation of four companies and 82 patents.

The 43-year-old professor of bioengineering and applied physics also created a noninvasive prenatal testing method for detecting Down syndrome.

Stanford University officials said in a prepared statement that Quake is using a similar approach to provide tests that can show earlier and more easily whether an organ transplant recipient is rejecting an organ donation.

Quake said Monday he was "incredibly excited and humbled" by the prize.

"Hopefully, it will give me a little more credibility with the investment community as we try to commercialize our inventions," the professor told The Associated Press.

Inventor Jerome H. Lemelson and his wife founded the Lemelson-MIT Program at the university in 1994. MIT said the award Quake won is known as the "Oscar for inventors" and recognizes people who translate ideas into innovations that improve the world.

Go here to read the rest:
Stanford professor wins $500K MIT invention prize

NEWARK, N. J., May 31, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (AOBI) (the "Company"), today announced that it received written notification on May 25, 2012, from the NYSE Regulation, Inc. staff, on behalf of the New York Stock Exchange LLC ("NYSE"), that the staff had determined to immediately suspend trading in the common stock of the Company and file a delisting application with the United States Securities and Exchange Commission (the "SEC") pursuant to Section 804.00 of the Listed Company Manual. The staff stated in its notice that it had determined that the Company no longer meets the standard for continued listing on the NYSE and that it is necessary and appropriate for the protection of investors to immediately suspend trading in its common stock and initiate delisting proceedings.Trading in the Company's common stock on the NYSE had been halted since March 16, 2012.

As a result of the above actions, on Tuesday, May 29, 2012, the Company's common stock commenced quotation on the OTC Markets under the ticker symbol "AOBI."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements.The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, may cause actual results or events to differ materially from those described in the forward looking statements in this press release.The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:

Kewa Luo 646-367-1765

Read more from the original source:
American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of ...

Skip image

Brittany Hutchinson demonstrating the pipette that she raised money to fund. through the Donors Choose program.

By Whitney Hamrick | May 24, 2012

Teachers daunted by the shortage of school funding in Seminole County may have a source of relief.

Brittany Hutchinson, who teaches bioengineering at Lyman High School in Longwood, raised more than $700 to pay for micropipettes and other equipment through her partnership with a website called donorschoose.org.

"Ms. Hutchinson did a great job of promoting her project through donorschoose.org," said Tony Williams, who is the Horace Mann representative for Seminole County. "We work with the schools and we want to see the educators succeed."

Donors Choose is a nonprofit organization that provides a platform for donors and public school teachers to connect in order to fund necessary classroom materials they would otherwise have to do without in a tough economy.

The website was established by Horace Mann, an insurance company founded by teachers to focus on the financial needs of educators. The website was first launched in February 2011 and has since contributed $1.3 million to school projects nationwide.

Williams arrived in Seminole County three months ago, and during his search to learn more about the community, he found Hutchinson's profile.

The rest is here:
Teachers experiment with fundraising pays off

CHICAGO, IL--(Marketwire -05/15/12)- The NanoFabrication Systems Division of NanoInk is pleased to announce that it has reached a non-exclusive agreement with the Research Institute of Biomolecule Metrology Co., Ltd. (RIBM) to serve as a distributor in Japan. RIBM will distribute NanoInk's desktop nanofabrication equipment, including the NLP 2000 System and the DPN 5000 System, which has a wide range of applications ranging from nanoarray-based protein analysis to nano-bioengineering and biomaterial research. As a leader in the visualization and measurement of biomolecules, RIBM aims to spearhead technological advancements in the field of nano-biotechnology.

"RIBM is a leading player in the Japanese nano-biology industry and has already established a strong relationship with NanoInk's target customers in Japan. Its sales and technical teams have the in-depth knowledge required to understand the scientific instrument market and it has proven expertise in selling technically-sophisticated equipment into that space. With these strengths, RIBM is the ideal partner for driving sales of NanoInk's unique nanofabrication platforms for use in life science and bioengineering applications," said Oliver Yeh, General Manager, NanoInk's NanoFabrication Systems Division, Asia-Pacific region. "We look forward to a close and successful long-term partnership with RIBM as we expand our reach in Japan by promoting the unique capabilities and benefits of the NanoInk line of patterning systems."

"We are delighted to be appointed as a distributor for NanoInk's products in Japan's life science and bioengineering markets," said Dr. Takashi Morii, Director of the Biomolecule Metrology Division at RIBM. "NanoInk's product lines are complementary to our current product portfolio and are attractive to our targeted nano-biotechnology markets. We look forward to working with the NanoInk team."

NanoInk's NanoFabrication Systems Division brings sophisticated nanofabrication to the laboratory in an easy to use and affordable platform. NanoInk's NLP 2000 System is a desktop instrument that allows researchers to rapidly design and create custom engineered and functionalized surfaces by using Dip Pen Nanolithography (DPN) to transfer minute amounts of materials over a large, environmentally controlled work area. With the ability to create custom patterns of nano-to-microscale features in under an hour, the NLP 2000 System is valuable for protein and biomolecular patterning, microstructure and biosensor functionalization, cell biology and polymer printing applications.

The DPN 5000 System is a full-featured, dedicated instrument for versatile nanopatterning of a variety of materials with nanoscale accuracy and precision. With its user-friendly interface, it is possible to easily design complex patterns while also precisely controlling tip movements during the writing process. The DPN 5000 System is the ideal platform for nanofabrication, nanomaterials and biomaterials applications that exhibit nanoscale printing, imaging and registration requirements.

With locations in Tsukuba, Tokyo, and Hiroshima, RIBM specializes in biomolecule metrology, molecular imaging and food & environmental analysis applications. It develops, manufactures, and sells SPM equipment and conducts contract measurement services using SPM. In addition, it manufactures and sells high-speed AFM for biology which can capture movie images of moving molecules. RIBM also markets nano-measurement equipment and inspects food and environmental samples for genetic modifications, allergens, viruses and residual agricultural chemicals.

To obtain more information or to place an order through RIBM for NanoInk's desktop nanofabrication systems, please email Dr. Takashi Morii at morii@ribm.co.jp. More background on RIBM is available at: http://www.ribm.co.jp/index-e.htm.

For information on additional NanoInk distributors, visit: http://nanoink.net/distributors.html. More detail about the NanoFabrication Systems Division of NanoInk is available at: http://www.nanoink.net/divisions.html#NanoFabrication.

About NanoInkNanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life sciences, engineering, pharmaceutical, and education industries. Using Dip Pen Nanolithography (DPN), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create micro-and nanoscale structures from a variety of materials on a range of substrates. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Headquartered in the Illinois Science + Technology Park, north of Chicago, NanoInk currently has several divisions including the NanoFabrication Systems Division, the Nano BioDiscovery Division, the NanoProfessor Division and the NanoGuardian Division. For more information on products and services offered by NanoInk, Inc., visit http://www.nanoink.net.

NanoInk, the NanoInk logo, Dip Pen Nanolithography, DPN, and NanoProfessor are registered trademarks of NanoInk, Inc.

Excerpt from:
NanoInk Expands Presence in Japan With Prestigious New Distributor

Bioengineering, an academic unit of the School of Engineering and Applied Sciences, is on the table to move to Allston, according to several University officials.

According to University Provost Alan M. Garber 76, the Harvard administrators are considering moving portions of bioengineering, a growing sector within SEAS, to its proposed Allston Science Centerwhich was originally conceptualized as a mecca for stem cell researchupon the sites completion.

Garber said that University officials have yet to finalize academic planning for Allston.

Well have more to say about our academic direction for the building in June, but among the groups that seem to be particularly promising fits for Allston are bioengineering and stem-cell research, Garber said.

Kevin Casey, University associate vice president of public affairs and communications, said that Harvard is carefully considering its options for Allston development.

For each area, the provost has been meeting extensively with faculty and deans to further develop the plans in each area, and with fundraising leadership to determine possible strategies for philanthropic support, Casey wrote in an email. This planning process is ongoing.

SEAS Dean Cherry A. Murray, who also serves as the area dean for bioengineering, declined to comment.

In 2007, the University released its Institutional Master Plan for Allston, which included the creation of a $1 billion science complex in Allston. in Allston. However, development on the Allston Science Complex was halted in 2009 when the financial crisis delivered a significant blow to the University endowment.

In 2011, the University resumed planning for Allston development, including the its science complexnow called the Allston Science Center.

The development of the Allston Science Center is just one piece of the two-phase plan for Allston construction released by University Executive Vice President Katie N. Lapp.

Read the rest here:
Bioengineering May Relocate To Allston

Researchers at the Institute of Bioengineering and Nanotechnology (IBN) have developed a miniaturised biochip, the Droplet Array, to investigate the effect of drugs on cancer stem cells. -- PHOTO: IBN

Researchers at the Institute of Bioengineering and Nanotechnology (IBN) have developed a miniaturised biochip to investigate the effect of drugs on cancer stem cells.

The miniaturised biological assay, dubbed the Droplet Array and developed by a team of researchers led by IBN executive director, Professor Jackie Y. Ying, will make it easier for drug screenings using limited samples.

The new technology could boost the development of more effective cancer drugs, according to a statement released by IBN.

In a tumour, cancer stem cells form a small and distinct class of cancer cells that are more resistant to chemotherapy. They can produce and differentiate into different cell types. If they are not eradicated, they can cause cancer to recur.

More here:
Researchers in Singapore develop cancer stem cell biochip